Cargando…

Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?

BACKGROUND: Many research papers claim that patients with specific psychiatric disorders (major depressive disorder, posttraumatic stress disorder, borderline personality disorder, alcohol use disorder, and others) have smaller hippocampi, but most of those reports compared patients to healthy contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gosnell, Savannah N., Meyer, Matthew J., Jennings, Cassandra, Ramirez, Danna, Schmidt, Jake, Oldham, John, Salas, Ramiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219869/
https://www.ncbi.nlm.nih.gov/pubmed/32440605
http://dx.doi.org/10.1177/2470547020906799
_version_ 1783533055135186944
author Gosnell, Savannah N.
Meyer, Matthew J.
Jennings, Cassandra
Ramirez, Danna
Schmidt, Jake
Oldham, John
Salas, Ramiro
author_facet Gosnell, Savannah N.
Meyer, Matthew J.
Jennings, Cassandra
Ramirez, Danna
Schmidt, Jake
Oldham, John
Salas, Ramiro
author_sort Gosnell, Savannah N.
collection PubMed
description BACKGROUND: Many research papers claim that patients with specific psychiatric disorders (major depressive disorder, posttraumatic stress disorder, borderline personality disorder, alcohol use disorder, and others) have smaller hippocampi, but most of those reports compared patients to healthy controls. We hypothesized that if psychiatrically matched controls (psychiatric control, matched for demographics and psychiatric comorbidities) were used, much of the biomarker literature in psychiatric research would not replicate. We used hippocampus and amygdala volume only as examples, as these are very commonly replicated results in psychiatry biomarker research. We propose that psychiatry biomarker research could benefit from using psychiatric controls, as the use of healthy controls results in data that are not disorder-specific. METHOD: Hippocampus/amygdala volumes were compared between major depressive disorder, sex-/age-/race-matched healthy control, and psychiatric control (N = 126/group). Similar comparisons were performed for posttraumatic stress disorder (N = 67), borderline personality disorder (N = 111), and alcohol use disorder (N = 136). RESULTS: Major depressive disorder patients had smaller left (p = 8.79 × 10(−3)) and right (p = 3.13 × 10(−3)) hippocampal volumes than healthy control. Posttraumatic stress disorder had smaller left (p = 0.018) and right (p = 8.64 × 10(−4)) hippocampi than healthy control. Borderline personality disorder had smaller right hippocampus (p = 7.90 × 10(−3)) and amygdala (p = 1.49 × 10(−3)) than healthy control. Alcohol use disorder had smaller right hippocampus (p = 0.034) and amygdala (p = .024) than healthy control. No differences were found between any of the four diagnostic groups and psychiatric control. CONCLUSION: When psychiatric controls were used, there was no difference in hippocampal or amygdalar volume between any of the diagnoses studied and controls. This strategy (keeping all possible relevant variables matched between experimental groups) has been used to advance science for hundreds of years, and we propose should also be used in biomarker psychiatry research.
format Online
Article
Text
id pubmed-7219869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72198692020-05-21 Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities? Gosnell, Savannah N. Meyer, Matthew J. Jennings, Cassandra Ramirez, Danna Schmidt, Jake Oldham, John Salas, Ramiro Chronic Stress (Thousand Oaks) Original Article BACKGROUND: Many research papers claim that patients with specific psychiatric disorders (major depressive disorder, posttraumatic stress disorder, borderline personality disorder, alcohol use disorder, and others) have smaller hippocampi, but most of those reports compared patients to healthy controls. We hypothesized that if psychiatrically matched controls (psychiatric control, matched for demographics and psychiatric comorbidities) were used, much of the biomarker literature in psychiatric research would not replicate. We used hippocampus and amygdala volume only as examples, as these are very commonly replicated results in psychiatry biomarker research. We propose that psychiatry biomarker research could benefit from using psychiatric controls, as the use of healthy controls results in data that are not disorder-specific. METHOD: Hippocampus/amygdala volumes were compared between major depressive disorder, sex-/age-/race-matched healthy control, and psychiatric control (N = 126/group). Similar comparisons were performed for posttraumatic stress disorder (N = 67), borderline personality disorder (N = 111), and alcohol use disorder (N = 136). RESULTS: Major depressive disorder patients had smaller left (p = 8.79 × 10(−3)) and right (p = 3.13 × 10(−3)) hippocampal volumes than healthy control. Posttraumatic stress disorder had smaller left (p = 0.018) and right (p = 8.64 × 10(−4)) hippocampi than healthy control. Borderline personality disorder had smaller right hippocampus (p = 7.90 × 10(−3)) and amygdala (p = 1.49 × 10(−3)) than healthy control. Alcohol use disorder had smaller right hippocampus (p = 0.034) and amygdala (p = .024) than healthy control. No differences were found between any of the four diagnostic groups and psychiatric control. CONCLUSION: When psychiatric controls were used, there was no difference in hippocampal or amygdalar volume between any of the diagnoses studied and controls. This strategy (keeping all possible relevant variables matched between experimental groups) has been used to advance science for hundreds of years, and we propose should also be used in biomarker psychiatry research. SAGE Publications 2020-02-26 /pmc/articles/PMC7219869/ /pubmed/32440605 http://dx.doi.org/10.1177/2470547020906799 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Gosnell, Savannah N.
Meyer, Matthew J.
Jennings, Cassandra
Ramirez, Danna
Schmidt, Jake
Oldham, John
Salas, Ramiro
Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title_full Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title_fullStr Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title_full_unstemmed Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title_short Hippocampal Volume in Psychiatric Diagnoses: Should Psychiatry Biomarker Research Account for Comorbidities?
title_sort hippocampal volume in psychiatric diagnoses: should psychiatry biomarker research account for comorbidities?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219869/
https://www.ncbi.nlm.nih.gov/pubmed/32440605
http://dx.doi.org/10.1177/2470547020906799
work_keys_str_mv AT gosnellsavannahn hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT meyermatthewj hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT jenningscassandra hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT ramirezdanna hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT schmidtjake hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT oldhamjohn hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities
AT salasramiro hippocampalvolumeinpsychiatricdiagnosesshouldpsychiatrybiomarkerresearchaccountforcomorbidities